About UsMembershipMarketplaceResourcesGlobal Business Atlas
Top AI CompaniesTop Blockchain Influencers & AuthorsTop Global Digital AgenciesBusinessabc Country IndexesTop Accelerators and Chambers of CommerceTop Public Companies by MarketcapBusinessabc Education IndexesTop Malaysian Companies
DirectoryCompaniesLeadersInvestorsUniversitiesOrganisations
Loading wiki page…

Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Learn More
Last Updated: 2026
Chugai Pharmaceutical image

Chugai Pharmaceutical

CategoryPharma and Life Sciences, Technology
Summary
History
Mission
Vision
References
Summaryarrow

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. 

The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; osteoporosis, including Actemra, Edirol, and Bonviva; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, haematology, ophthalmology, and other diseases. 

Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

Historyarrow

The headquarters and the factories in Ikebukuro, Sakai and Takada were destroyed in World War II, the headquarters were relocated to Takada, and the factory in Takada was rebuilt. In 1969,  The name of Fukushima Kasai Co Ltd. is changed to Eiko Kasei Co Ltd., after the merger of Fukushima Kasai Co Ltd. and Fukuma Kasau Co. Ltd.

In March 2015 the company announced it would co-commercialise Athersys's stem cell therapy for ischemic strokes in Japan. The deal could yield upwards of US$205 million.

Missionarrow

“Dedicate ourselves to adding value by creating and delivering innovative products and services for the medical community and human health around the world.”

 

Visionarrow

“We will be a top innovator in the healthcare industry, achieving patient-centred, high-level, sustainable medical care, based on our unique science and technology capabilities.”

Referencesarrow

https://en.wikipedia.org/wiki/Chugai_Pharmaceutical_Co.

https://www.crunchbase.com/organization/chugai-pharmaceuticals

https://sec.report/CIK/0001172626

https://finance.yahoo.com/quote/CHGCF/

https://www.comparably.com/companies/chugai-pharmaceutical-company

https://companiesmarketcap.com/largest-companies-by-revenue/

https://www.globaldata.com/company-profile/chugai-pharmaceutical-co-ltd/

https://www.bloomberg.com/quote/4519:JP

https://www.investing.com/equities/chugai-pharmaceutical-co.,-ltd.

https://www.reuters.com/companies/4519.T

Share

Leadership team
T
Toshiya Sasai (Exec. of Investor Relations Group & Corp. Communications Department)
M
Mr. Toshiaki Itagaki (Head of Fin. Supervisory Division, CFO, Exec. VP & Director)
Industries
Pharma and Life Sciences, Technology
Products / Services
Biotechnology, Clinical Trials, Health Care, Medical
Number of Employees
1,000 - 20,000
Established
1925-03-10
Company Type
Public Limited Company
Company Registration
SEC CIK number: 0001172626
Net Income
$1B – $20B
Revenue
$1B+
Traded as
4591
Website
https://www.chugai-pharm.co.jp
Social Media
linkedinyoutubex
Last Updated: 2026
Logo

Businessabc provides digital business directory, digital blockchain AI certification, resources, and marketplace for businesses, organisations, and professionals.

Contacts

Email
Contact

Follow Us

Created Produced

Partner logo
Partner logo

Tech AI Media Platforms

Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo

Copyright 2026 © Businessabc powered by

Powered by ztudium group

DisclaimerPrivacy PolicyTerms of Service
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo